Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis began in June, with top-line results expected in 2H 2028.
CAPTIVATE Phase 3 CIDP interim analysis showed a 75% response rate in the first 40 Part A completers; MMN Phase 2 top-line data are due in December 2026.
Q2 financial results
Dianthus Therapeutics posted a Q2 net loss of USD 50.22 million, widening from USD 31.63 million a year earlier.
Revenue rose to USD 761,000 from USD 193,000; R&D expenses climbed to USD 48.69 million from USD 26.25 million.
G&A costs increased to USD 13.56 million from USD 8.87 million; cash, cash equivalents and investments totaled about USD 1.2 billion at June 30.
DNTH•
